GSK · Pharma and healthcare · one day
GSK (GSK): news on Tuesday 27 October 2026
News from the 24 hours to Tuesday morning, 27 October 2026.
Tone of the day
+9.3strongly positive
+9.3
Relevant headlines29
Stories8
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by encouraging cancer trial data presented at ESMO, covering bone, ovarian and rectal cancer. Sentiment is clearly positive, tempered slightly by a bank's continued Sell rating.
What drove it
- ESMO cancer trial data
- rectal cancer results
- analyst ratings
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 21 Oct | +10.0 | 26 |
| Thu 22 Oct | +10.0 | 37 |
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
| Tue 27 Oct | +9.3 | 29 |
8 stories · 29 headlines · strongest first
Pharma and healthcare on 27 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK reports Jemperli rectal cancer trial results +10.07 headlines today · 8 in all, since 25 October · GSK reported Jemperli data showing a 76% complete response rate in rectal cancer, with no recurrences so far among responders. | ||
| +10.0 | Most rectal patients avoided surgery and chemotherapy after treatment. | |
| +10.0 | High tumour clearance rate in rectal cancer trial. | |
| +10.0 | Official release confirms high complete response rate. | |
| +9.2 | Promising results in two tumour types. | |
| +9.2 | Favourable trial outcomes in two cancer types. | |
| +9.2 | Favourable interim mid-stage rectal cancer findings. | |
| +9.2 | Responders showed no relapse so far in rectal cancer trial. | |
| GSK and Hansoh bone cancer drug slows disease progression in China trial +10.05 headlines today · A late-stage China study of ris-rez with Hansoh met its primary endpoint and delayed disease progression in bone cancer. | ||
| +10.0 | Trial showed large improvement in progression-free survival for bone cancer drug. | |
| +10.0 | Late-stage China study showed slower disease progression. | |
| +10.0 | GSK and Hansoh's drug prolonged survival in a bone-cancer trial. | |
| +10.0 | A drug from GSK and Hansoh prolonged survival in a bone-cancer trial. | |
| +10.0 | China trial achieved its main goal. | |
| GSK presents ovarian cancer results for mo-rez at ESMO +7.35 headlines today · 9 in all, since 25 October · GSK announced positive Phase Ib mo-rez data in ovarian cancer with a 62% response rate, reported by several outlets. | ||
| +8.3 | Updated early-stage ovarian cancer data presented by the company. | |
| +8.3 | Trial in ovarian cancer produced a 62% response rate. | |
| +8.3 | Official release of encouraging ovarian cancer phase data. | |
| +7.5 | Two oncology datasets shown at major conference. | |
| +6.7 | Several late-stage cancer studies in progress alongside ovarian update. | |
| GSK's return to oncology draws press analysis +9.23 headlines today · Bloomberg and STAT discussed GSK's cancer push and the data it is producing. | ||
| +10.0 | Cancer push yielding encouraging trial results. | |
| +10.0 | Oncology strategy beginning to deliver results. | |
| +7.5 | Company anticipates regulatory clearance for a new oncology medicine. | |
| Brokers rate GSK +1.53 headlines today · 5 in all, since 22 October · JP Morgan reaffirmed a Sell rating and Jefferies issued a 2,500p target. | ||
| +7.5 | New product approval alongside analyst price target. | |
| −6.7 | Bank maintains negative recommendation on the shares. | |
| +5.0 | Broker sets a price target above recent levels. | |
| GSK share price moves and technical views −0.73 headlines today · 5 in all, since 24 October · Outlets reported on GSK's share price moves and technical levels. | ||
| +2.5 | Modest share price gain, technical commentary only. | |
| +2.5 | Small pre-market share price rise. | |
| +0.8 | Shares flat, trading in a narrow range. | |
| GSK third-quarter results due 28 October +2.02 headlines today · 4 in all, since 24 October · Previews ahead of the 28 October results noted a forecast of $1.33 per share in earnings, plus key facts. | ||
| +6.7 | Summary of ovarian trial response rate and results. | |
| +0.8 | Routine earnings expectations preview. | |
| GSK share price and valuation commentary +3.31 headline today · 28 in all, since 16 October · Simply Wall Street commented on GSK's valuation after a five-year run. | ||
| +5.8 | Commentary sees shares as undervalued after strong multi-year performance. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.